Leadership Transition to Propel Single-Cell Biotech Growth

Cytosurge AG, a biotech leader in single-cell manipulation and cell-line engineering, has announced a leadership transition effective January 1, 2025. After 12 years as CEO, co-founder Dr. Pascal Behr will step into a strategic role as Delegate of the Board of Directors, continuing to guide the company’s direction from a broader vantage point. Stepping into the CEO position is Simon Egli, previously Chief Commercial Officer, signaling the company’s confidence in his leadership for the next phase of growth.

“On behalf of the Board, I want to thank Pascal for his outstanding leadership,” said Martin Gertsch, Chairman of the Board. “Under his guidance, Cytosurge achieved major milestones: over 140 FluidFM® systems are now in use worldwide, and our technology has been featured in more than 150 peer-reviewed publications. He also oversaw the successful launch of the CellEDIT Service, setting a new benchmark in genetically engineered cell lines for research.”

Simon Egli brings more than a decade of life sciences industry experience to his new role. Before joining Cytosurge, he held senior leadership roles at INFORS HT, including Chief Commercial Officer and CEO of Infors USA, Inc. He earned an International Executive MBA from the Rochester-Bern Executive Programs and holds a degree in Biotechnology from ZHAW Zurich University of Applied Sciences.

Reflecting on his transition, Pascal Behr said, “I’m incredibly proud of everything the team has accomplished. Cytosurge is well-positioned for the future, and I have full confidence in Simon’s ability to lead the company forward.”

“I’m honored to take on this role,” Simon Egli added. “With such a strong foundation and a dedicated team, we’re ready to drive the next wave of innovation in cell-line engineering and single-cell profiling.”